New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:53 EDTTEVAGeneric Copaxone approval very unlikely this quarter, says Jefferies
Jefferies says it sees a lower probability for a near-term generic Copaxone approval following the expiry of Orange Book listed patents on May 24. The firm is also more positive on the ex-U.S. outlook of Copaxone following yesterday's positive EU patent office decision. Jefferies sees a "very low probability" of generic Copaxone approval this quarter, and perhaps 50% in 2014. It has a Buy rating on the Teva with a $61 price target.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 14, 2014
11:23 EDTTEVABIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use